|
Press Release |
24 June 2009 |
LiDCO Group Plc
("LiDCO" or the "Company")
TR-1: Notification of Major Interests in Shares
LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, today gives notification of major interests in shares.
|
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: |
Lidco Group PLC |
||
|
2. Reason for notification (yes/no) |
|||
|
An acquisition or disposal of voting rights |
YES |
||
|
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
NO |
||
|
An event changing the breakdown of voting rights |
NO |
||
|
Other (please specify):______________ |
NO |
||
|
3. Full name of person(s) subject to notification obligation: |
Ingalls & Snyder LLC ("I&S") and Ingalls & Snyder Value Partners LP ("ISVP"). |
||
|
4. Full name of shareholder(s) (if different from 3): |
I&S, on behalf of its clients, has dispositive authority over (i.e. the power and authorisation to sell at I&S's discretion) 23,855,746 shares. In respect of 13,820,000 of such 23,855,746 shares ISVP (as beneficial owner) shares dispositive authority with I&S and has voting authority. So in respect of the 13,820,000 shares beneficially held by ISVP, I&S has and ISVP share dispositive authority and ISVP has voting authority. |
||
|
5. Date of transaction (and date on which the threshold is crossed or reached if different): |
June 23, 2009 |
||
|
6. Date on which issuer notified: |
June 24, 2009 |
||
|
7. Threshold(s) that is/are crossed or reached: |
Interest in excess of 13% of issued share capital. |
||
|
8: Notified Details |
|||||||
|
A: Voting rights attached to shares |
|||||||
|
Class/type of shares If possible use ISIN code |
Situation previous to the triggering transaction |
Resulting situation after the triggering transaction |
|||||
|
Number of shares |
Number of voting rights |
Number of shares |
Number of voting rights |
Percentage of voting rights |
|||
|
Direct |
Indirect |
Direct |
Indirect |
||||
|
Ordinary Shares of 0.5 pence ISIN GB0030546849 |
19,018,746 |
- |
23,855,746 |
See note 4 above. I&S has dispositive authority over 23,855,746 shares and ISVP has voting authority and shares dispositive authority in respect of 13,820,000 of such shares. |
- |
13.71% (Note: For these purposes we have assumed that dispositive authority is equivalent to voting rights). |
- |
|
B: Financial Instruments N/A |
||||
|
Resulting situation after the triggering transaction |
||||
|
Type of financial instrument |
Expiration date |
Exercise/ conversion period/date |
No. of voting rights that may be acquired (if the instrument exercised/converted) |
Percentage of voting rights |
|
|
|
|
|
|
|
Total (A+B) |
|
|
Number of voting rights |
Percentage of voting rights |
|
23,855,746 (Note: For these purposes we have assumed that dispositive authority is equivalent to voting rights.) |
13.71% (Note: For these purposes we have assumed that dispositive authority is equivalent to voting rights). |
|
9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable: |
|
N/A |
|
Proxy Voting: |
|
|
10. Name of proxy holder: |
N/A |
|
11. Number of voting rights proxy holder will cease to hold: |
N/A |
|
12. Date on which proxy holder will cease to hold voting rights: |
N/A |
|
13. Additional information: |
|
|
14 Contact name: |
Edward H. Oberst |
|
15. Contact telephone name: |
(001) (212) 269 7812 |
- ENDS -
For more information please contact:
|
LiDCO Group Plc |
|
|
Terry O'Brien - Chief Executive John Rowland - Company Secretary |
Tel: +44 (0)20 7749 1500 |
|
FinnCap |
|
|
Geoff Nash / Marc Young / Stephen Norcross |
+44 (0)20 7600 1658 |
Media enquiries
|
Abchurch Communications |
|
|
Heather Salmond / Stephanie Cuthbert / Simone Alves |
+44 (0)20 7398 7728 |
|
|
About LiDCO Group Plc
LiDCO is a leading supplier of minimally invasive hemodynamic monitoring equipment and disposables. These are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.
The Company's manufacturing facility is in Hoxton, London and its current products are:
* LiDCOplus and PulseCO monitors: these computer-based platforms are used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid volume (PPV% and SVV%)
* LiDCO disposables: used in conjunction with the LiDCOplus Monitor for accurate measurement of cardiac output in a minimally invasive manner
* LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase
* LiDCOlive: a software product in development for the remote display of hemodynamic monitoring parameters derived through use of the LiDCOplus or LiDCOrapid monitors
* LiDCOrapid : our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care
Distribution Network:
The Company has now achieved registration of its products in 14 markets in Europe, the USA, Brazil, South Korea and Japan. It sells direct in the UK and USA, and elsewhere through a worldwide network of speciality critical care and anesthesia distributors.